Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MLG068
MIFTS: 46

Malignant Glioma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Malignant Glioma

About this section

MalaCards integrated aliases for Malignant Glioma:

Name: Malignant Glioma 12 54 6 15 37 71
Malignant Neuroglial Tumor 12
Glioma, Malignant 12
Malignant Gliomas 15
Glial Cell Tumor 12
Neuroglial Tumor 12
Glioma 43

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Bone diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3070
MeSH 43 D005910
NCIt 49 C3059 C4822
UMLS 71 C0017638 C0555198
Sources

Summaries for Malignant Glioma

About this section
Disease Ontology : 12 A cell type cancer that has material basis in glial cells and is located in brain or located in spine.

MalaCards based summary : Malignant Glioma, also known as malignant neuroglial tumor, is related to astrocytoma and glioma. An important gene associated with Malignant Glioma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways is Glioma. The drugs Midazolam and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial.

Sources

Related Diseases for Malignant Glioma

About this section

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Malignant Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1085)
# Related Disease Score Top Affiliating Genes
1 astrocytoma 32.7 PVT1 NEAT1 MIR155HG HOXA11-AS HOXA-AS3 HOTAIRM1
2 glioma 32.4 PVT1 NEAT1 HOXA11-AS HOTTIP HOTAIR GAS5
3 glioma susceptibility 1 31.3 XIST PWAR5 MIR155HG HOXA-AS3 HOTAIRM1 HOTAIR
4 b-cell lymphoma 30.8 PVT1 HOTAIR GAS5 ATM
5 retinitis pigmentosa 11 30.7 XIST PVT1 NEAT1 HOTAIR
6 leukemia 30.5 NEAT1 HOTAIRM1 HOTAIR GAS5 CDKN2B-AS1 ATM
7 renal cell carcinoma, nonpapillary 30.5 PVT1 HOTAIR GAS5 CRNDE CASC2 ATM
8 melanoma 30.5 XIST PVT1 HOXA-AS2 HOTAIRM1 HOTAIR GAS5
9 thyroid cancer, nonmedullary, 1 30.4 NEAT1 HOTTIP HOTAIR
10 nasopharyngeal carcinoma 30.4 XIST PVT1 NEAT1 HOTAIR GAS5 CDKN2B-AS1
11 leukemia, acute myeloid 30.4 HOTAIRM1 HOTAIR CDKN2B-AS1 CCDC26 ATM
12 hepatocellular carcinoma 30.3 XIST PVT1 NEAT1 HOXA11-AS HOXA-AS2 HOTTIP
13 laryngeal squamous cell carcinoma 30.3 NEAT1 HOXA11-AS HOTAIR CDKN2B-AS1
14 pancreatic ductal adenocarcinoma 30.3 PVT1 HOTTIP HOTAIRM1 HOTAIR
15 burkitt lymphoma 30.2 PVT1 NEAT1 MIR155HG ATM
16 esophageal cancer 30.2 XIST PVT1 HOXA11-AS HOTTIP HOTAIR GAS5
17 pancreatic cancer 30.1 XIST PVT1 NEAT1 HOTTIP HOTAIR GAS5
18 ovarian cancer 30.1 XIST PVT1 NEAT1 HOXA11-AS HOTAIR GAS5
19 osteogenic sarcoma 30.1 XIST PVT1 NEAT1 HOXA11-AS HOTTIP HOTAIR
20 myeloma, multiple 30.1 PVT1 HOTAIR GAS5 ATM
21 gallbladder cancer 30.0 HOXA-AS2 HOTAIR CRNDE CDKN2B-AS1
22 cervical cancer 30.0 PVT1 NEAT1 HOXA11-AS HOTAIR GAS5 CRNDE
23 gastric cancer 30.0 XIST PVT1 NEAT1 HOXA11-AS HOXA-AS2 HOTTIP
24 retinitis pigmentosa 29.9 XIST PVT1 NEAT1 HOTAIR GAS5 CRNDE
25 colorectal cancer 29.8 XIST PVT1 NEAT1 HOXA11-AS HOXA-AS2 HOTTIP
26 acute promyelocytic leukemia 29.8 PVT1 NEAT1 HOXA-AS2 HOTAIRM1
27 breast cancer 29.8 XIST PVT1 NEAT1 MIR155HG HOXA11-AS HOXA-AS2
28 prostate cancer 29.7 XIST PVT1 NEAT1 HOTTIP HOTAIR GAS5
29 hematologic cancer 29.6 XIST PVT1 CCDC26 ATM
30 optic pathway glioma 12.5
31 glioma susceptibility 2 12.5
32 childhood brain stem glioma 12.5
33 third ventricle chordoid glioma 12.4
34 subependymal glioma 12.3
35 chordoid glioma 12.3
36 childhood optic nerve glioma 12.3
37 spinal cord glioma 12.3
38 glioma susceptibility 6 12.3
39 glioma susceptibility 8 12.3
40 glioma susceptibility 5 12.3
41 glioma susceptibility 7 12.3
42 glioma susceptibility 4 12.2
43 adult brainstem mixed glioma 12.2
44 visual pathway and hypothalamic glioma, childhood 12.1
45 limbic encephalitis with lgi1 antibodies 12.0
46 meningioma, familial 11.6
47 malignant ependymoma 11.6
48 mismatch repair cancer syndrome 11.6
49 encephalocraniocutaneous lipomatosis 11.6
50 nasal glial heterotopia 11.5

Graphical network of the top 20 diseases related to Malignant Glioma:



Diseases related to Malignant Glioma
Sources

Symptoms & Phenotypes for Malignant Glioma

About this section
Sources

Drugs & Therapeutics for Malignant Glioma

About this section

Drugs for Malignant Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 564)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
3
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
4 Anticonvulsants Phase 4
5 Anti-Anxiety Agents Phase 4
6 Excitatory Amino Acid Antagonists Phase 4
7 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Analgesics Phase 4
10 Anesthetics Phase 4
11 Hypnotics and Sedatives Phase 4
12 Adrenergic Agents Phase 4
13 Adrenergic alpha-Agonists Phase 4
14 Adrenergic Agonists Phase 4
15
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
16
Lenograstim Approved, Investigational Phase 3 135968-09-1
17
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
18
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
19
Dalteparin Approved Phase 3 9005-49-6
20
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
21
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
22
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
23
Ondansetron Approved Phase 3 99614-02-5 4595
24
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
25
Donepezil Approved Phase 3 120014-06-4 3152
26
Trioxsalen Approved Phase 3 3902-71-4 5585
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
28
Thioguanine Approved Phase 3 154-42-7 2723601
29
Ethanol Approved Phase 2, Phase 3 64-17-5 702
30
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
31
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
32
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
33
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
34
Vorinostat Approved, Investigational Phase 2, Phase 3 149647-78-9 5311
35
Carmustine Approved, Investigational Phase 3 154-93-8 2578
36
Etoposide Approved Phase 3 33419-42-0 36462
37
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
38
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
39
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
40
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
41
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
42
leucovorin Approved Phase 3 58-05-9 6006 143
43
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
44
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
45
Histamine Approved, Investigational Phase 3 51-45-6 774
46
Cyproheptadine Approved Phase 3 129-03-3 2913
47
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
48
Norepinephrine Approved Phase 3 51-41-2 439260
49
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
50
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 1473)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
5 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
7 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
8 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
9 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
10 Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study Unknown status NCT02150564 Phase 3
11 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
12 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
13 Randomized Controlled Multicenter Trial on the Impact of Presurgical Navigated Transcranial Magnetic Stimulation for Motor Mapping of Rolandic Lesions Unknown status NCT02879682 Phase 3
14 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
15 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
16 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
17 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
18 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
19 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
20 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
21 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
22 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
23 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
24 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
25 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
26 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
27 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
28 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
29 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
30 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
31 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
32 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
33 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
34 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
35 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
36 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
37 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
38 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
39 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
40 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
41 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
42 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
43 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
44 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
45 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
46 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
47 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
48 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
49 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
50 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine

Search NIH Clinical Center for Malignant Glioma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Malignant Glioma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Malignant Glioma:
ALD-451, bone marrow-derived cells for malignant glioma
Embryonic/Adult Cultured Cells Related to Malignant Glioma:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905

Cochrane evidence based reviews: glioma

Sources

Genetic Tests for Malignant Glioma

About this section
Sources

Anatomical Context for Malignant Glioma

About this section

MalaCards organs/tissues related to Malignant Glioma:

40
Brain, T Cells, Endothelial, Bone, Testes, Spinal Cord, Breast
Sources

Publications for Malignant Glioma

About this section

Articles related to Malignant Glioma:

(show top 50) (show all 5274)
# Title Authors PMID Year
1
Combination therapy with Gamma Knife radiosurgery and antisense EGFR for malignant glioma in vitro and orthotopic xenografts. 54 61
20428813 2010
2
Gene expression profiling predicts response to temozolomide in malignant gliomas. 54 61
20428759 2010
3
Akt signaling pathway: a target for radiosensitizing human malignant glioma. 61 54
20406894 2010
4
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma. 61 54
19893595 2010
5
MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. 54 61
20204284 2010
6
Review: on TRAIL for malignant glioma therapy? 61 54
20102513 2010
7
Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. 61 54
20188714 2010
8
Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation. 61 54
19939880 2010
9
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. 54 61
20167811 2010
10
Caffeine confers radiosensitization of PTEN-deficient malignant glioma cells by enhancing ionizing radiation-induced G1 arrest and negatively regulating Akt phosphorylation. 61 54
20103602 2010
11
MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience. 54 61
19856394 2010
12
Bevacizumab is active as a single agent against recurrent malignant gliomas. 54 61
20332478 2010
13
Evaluation of the prognostic value of CD44 in glioblastoma multiforme. 61 54
20150644 2010
14
Astrocyte elevated gene-1: a novel target for human glioma therapy. 54 61
20053777 2010
15
PAX6 suppression of glioma angiogenesis and the expression of vascular endothelial growth factor A. 61 54
19618119 2010
16
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. 61 54
19875977 2009
17
The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. 54 61
19409438 2009
18
Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. 54 61
19398149 2009
19
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. 54 61
19332770 2009
20
Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. 61 54
19300910 2009
21
MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. 54 61
19536818 2009
22
Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. 54 61
19637006 2009
23
Nuclear factor I regulates brain fatty acid-binding protein and glial fibrillary acidic protein gene expression in malignant glioma cell lines. 61 54
19540848 2009
24
Hypoxia up-regulates vascular endothelial growth factor in U-87 MG cells: involvement of TRPC1. 54 61
19446005 2009
25
Effect of IFN-beta on human glioma cell lines with temozolomide resistance. 61 54
19513561 2009
26
Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. 61 54
19465936 2009
27
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. 61 54
19416948 2009
28
Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. 54 61
19567132 2009
29
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. 61 54
19435839 2009
30
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 61 54
19248046 2009
31
Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2. 54 61
19429088 2009
32
KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway. 61 54
19385057 2009
33
Downregulating FPR restrains xenograft tumors by impairing the angiogenic potential and invasive capability of malignant glioma cells. 54 61
19233142 2009
34
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. 61 54
19293187 2009
35
Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. 54 61
18949017 2009
36
Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. 54 61
19252415 2009
37
Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. 61 54
19356600 2009
38
Activation of telomerase by human cytomegalovirus. 54 61
19318640 2009
39
Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. 54 61
19212678 2009
40
Stress response of a p53 homologue in the radioresistant Sf9 insect cells. 61 54
19296337 2009
41
cDNA clone, prokaryotic expression and purification of human interleukin-13 receptor [alpha]2 chain. 61 54
18677476 2009
42
Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. 61 54
18785269 2009
43
17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. 61 54
19027068 2009
44
Targeted therapies for malignant glioma: progress and potential. 54 61
19344189 2009
45
Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. 61 54
20192118 2009
46
The regulating role of mutant IkappaBalpha in expression of TIMP-2 and MMP-9 in human glioblastoma multiform. 54 61
19187648 2009
47
Novel anti-angiogenic therapies for malignant gliomas. 61 54
19007739 2008
48
Combination therapy for malignant glioma based on PTEN status. 61 54
18983237 2008
49
Antiangiogenic therapy in malignant gliomas. 61 54
18841047 2008
50
Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. 54 61
19067488 2008
Sources

Variations for Malignant Glioma

About this section

ClinVar genetic disease variations for Malignant Glioma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM):c.8786+1G>ASNV Pathogenic/Likely pathogenic 127463 rs17174393 11:108224608-108224608 11:108353881-108353881

Copy number variations for Malignant Glioma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 74684 13 110300000 115169878 Deletion Malignant glioma
2 75161 13 16300000 19500000 Deletion Malignant glioma
3 75381 13 19500000 32200000 Deletion Malignant glioma
4 77097 13 40100000 45200000 Deletion Malignant glioma
5 178248 3 69788586 70017488 Amplification MITF Malignant glioma
Sources

Expression for Malignant Glioma

About this section
Search GEO for disease gene expression data for Malignant Glioma.
Sources

Pathways for Malignant Glioma

About this section

Pathways related to Malignant Glioma according to KEGG:

36
# Name Kegg Source Accession
1 Glioma hsa05214
Sources

GO Terms for Malignant Glioma

About this section
Sources

Sources for Malignant Glioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....